Contemporary multidisciplinary treatment of pregnancy-associated breast cancer by Jane L Meisel et al.
a SpringerOpen Journal
Meisel et al. SpringerPlus 2013, 2:297
http://www.springerplus.com/content/2/1/297RESEARCH Open AccessContemporary multidisciplinary treatment of
pregnancy-associated breast cancer
Jane L Meisel1, Katherine E Economy1, Katherina Zabicki Calvillo1,4, Lydia Schapira2, Nadine M Tung3, Shari Gelber4,
Sandra Kereakoglow4, Ann H Partridge1,4 and Erica L Mayer1,4*Abstract
Breast cancer diagnosed during pregnancy poses unique challenges. Application of standard treatment algorithms
is limited by lack of level I evidence from randomized trials. This study describes contemporary multidisciplinary
treatment of pregnancy-associated breast cancer (PABC) in an academic setting and explores early maternal and
fetal outcomes. A search of the Dana-Farber/Harvard Cancer Center clinical databases was performed to identify
PABC cases. Sociodemographic, disease, pregnancy, and treatment information, as well as data on short-term
maternal and fetal outcomes, were collected through retrospective chart review. 74 patients were identified, the
majority with early-stage breast cancer. Most (73.5%) underwent surgical resection during pregnancy, including 40%
with sentinel lymph node biopsy and 32% with immediate reconstruction. A total of 36 patients received
anthracycline-based chemotherapy during pregnancy; of those, almost 20% were on a dose-dense schedule and
8.3% also received paclitaxel. 68 patients delivered liveborn infants; over half were delivered preterm (< 37 weeks),
most scheduled to allow further maternal cancer therapy. For the infants with available data, all had normal Apgar
scores and over 90% had birth weight >10th percentile. The rate of fetal malformations (4.4%) was not different
than expected population rate. Within a multidisciplinary academic setting, PABC treatment followed contemporary
algorithms without apparent increase in maternal or fetal adverse outcomes. A considerable number of preterm
deliveries were observed, the majority planned to facilitate cancer therapy. Continued attention to maternal and
fetal outcomes after PABC is required to determine the benefit of this delivery strategy.
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It is estimated that cancer complicates as many as 1 in 1000
pregnancies, with breast cancer as the most common asso-
ciated malignancy (Smith et al. 2001). Contemporary man-
agement of pregnancy-associated breast cancer (PABC)
encourages continuation of pregnancy during treatment.
Limitations in published data describing the safety of cancer
therapy in pregnancy create challenges and dilemmas in
clinical decision-making for providers caring for these pa-
tients. Prospective evaluation of the safety of antineoplastic
therapy during pregnancy is methodologically difficult;
therefore, most published data consist of case and cohort
series (Mir et al. 2008; Cardonick et al. 2012a; Loibl et al.
2012). Given the apparent rising incidence of PABC,* Correspondence: emayer@partners.org
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in any medium, provided the original work is pperhaps due to trends in delaying pregnancy (Andersson
et al. 2009; Litton & Theriault 2010), a greater understand-
ing of the pathologic features, treatment options, and ma-
ternal and fetal outcomes in PABC is critical.
PABC has been defined as breast cancer diagnosed dur-
ing pregnancy and up to one year postpartum. Although
much PABC research has considered this group as a whole,
it is worth considering two distinct subsets – those diag-
nosed during pregnancy, and those diagnosed in the post-
partum period (Borges & Schedin 2011). Physicians caring
for a pregnant patient with active breast cancer must select
treatment options which maximize benefits to the patient
while minimizing risks to the developing fetus. Given the
advances in contemporary management of breast cancer,
including use of taxanes, “dose dense” schedules, and senti-
nel lymph node biopsy, it is imperative to understand
whether or not these new treatments can be safely admin-
istered during pregnancy.n Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Table 1 Patient and tumor characteristics
Demographic (N = 74) Number Percent
Age at diagnosis (years)
Less than 30 11 14.9
30-34 26 35.1
35-39 29 39.2
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patients treated during pregnancy was identified at an
academic comprehensive cancer center. This study ex-
amined the distribution of tumor subtypes, treatment
decisions, and maternal and fetal outcomes within the
cohort, and evaluated the contemporary management of
PABC supported by a multidisciplinary team.≥40 8 10.8
Median age at diagnosis: 34 (range 25–40)
Gestational age at diagnosis (weeks)
0-12 (1st trimester) 25 33.8
13-27 (2nd trimester) 30 40.5












Delivery of liveborn infant(s) 68 91.9
Miscarried in 1st trimester 1 1.4Methods
A retrospective cohort of patients diagnosed with breast
cancer during pregnancy was created through a search of
the Dana Farber/Harvard Cancer Center (DF/HCC) clin-
ical database. Eligibility criteria included: a history of
pathologically confirmed breast cancer diagnosed during
pregnancy, at least two follow-up visits for treatment docu-
mented within the DF/HCC system (including the Dana-
Farber Cancer Institute, Massachusetts General Hospital,
Brigham and Women’s Hospital, and Beth Israel Deaconess
Medical Center) to identify continuous care, and age >
18 years. Medical oncologists, breast surgeons, and
maternal-fetal medicine specialists within the DF/HCC in-
stitutions were also queried to identify eligible patients
treated in their practices. Comprehensive review of the DF/
HCC database was used to gather patient information as
well as data on short-term maternal and fetal outcomes.
Statistical analysis was exploratory and descriptive in nature.
Institutional Review Board approval was obtained prior to








ER/PR Positive 46 62.2
HER2 Positive 25 33.8
Triple Negative 14 18.9
BRCA status
Genetic testing performed 50 67.6
BRCA 1 or 2 positive (N = 50) 6 12.0
BRCA 1 and 2 negative (N = 50) 44 88.0
Genetic testing not performed 24 32.4
Abbreviations: ER estrogen receptor, PR progesterone receptor, HER2 human
epidermal growth factor receptor 2.Results
Patient and disease characteristics
Seventy-four patients with PABC were identified who met
inclusion criteria. Detailed demographic and disease char-
acteristics are presented in Table 1. Most patients (62%) re-
ceived their diagnosis after 2005. The median age at
diagnosis was 34 years (range 25–40), with 63 (85.1%)
patients aged 30 or older at the time of diagnosis. The tim-
ing of presentation varied with 25 (33.8%) patients diag-
nosed in the first trimester, 30 (40.5%) in the second
trimester, and 19 (25.7%) in the third trimester. Sixty-eight
of the 74 patients (91.9%) carried their infants to term. One
patient miscarried and five pregnancies were electively
terminated during the first trimester, prior to initiating
cancer therapy.
The majority of patients (83.8%) were diagnosed with
early-stage disease; only two had metastatic disease at the
time of presentation. All were tested to evaluate tumor
hormone receptor and HER2 status; 46 (62.2%) were ER/
PR positive, 25 (33.8%) were HER2 positive, and 14 (18.9%)
had triple-negative breast cancer. A total of 50 patients
(67.6%) had BRCA testing performed, and in this subset, 6
(12.0%) tested positive for either a BRCA 1 or 2 mutation.Imaging
Most patients (67, 90.5%) underwent imaging to stage their
disease while pregnant. A total of 54 (73.0%) underwent
breast ultrasound, 30 (44.8%) underwent mammography,
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nority (8, 11.9%) underwent MRI of the breast, abdomen
and/or spinal cord, and of this subset, about half received
gadolinium. No patients underwent computed tomography
while pregnant.
Local therapy
Fifty of 68 patients (73.5%) who carried their pregnancies
to term underwent surgery during pregnancy (see Table 2).
Of this group, 39 underwent either lumpectomy or mastec-
tomy, and 11 underwent more than one operation,
resulting in a total of 37 lumpectomies and 25 mastecto-
mies performed during pregnancy in the overall cohort. A
total of 11 (17.7%) surgeries were performed during the
first trimester and 35 (56.5%) in the second trimester. Im-
mediate reconstruction was performed after 8 (32%) of the
mastectomies during pregnancy. In those having surgery,
sentinel lymph node biopsy was performed in 20 patients
(40.0%), with 12 procedures employing radiolabeled tracer
and 7 using blue dye.
Systemic therapy
Thirty-six of the 68 patients (52.9%) who carried pregnan-
cies to term received chemotherapy (see Table 3); 29
(80.6%) started chemotherapy in the second trimester and
7 (19.4%) started chemotherapy in the third trimester. No
chemotherapy was administered in the first trimester.Table 2 Surgical therapy for pregnancy associated breast
cancer
Surgical therapy (N = 68 patients delivered live
born infants, 50 patients underwent 62
surgical procedures)
Number Percent
Surgery during pregnancy (entire cohort N = 68)
Yes 50 73.5
No 18 26.5
Gestational age at time of operation (N = 62)
0-12 weeks (1st trimester) 11 17.7
13-27 weeks (2nd trimester) 35 56.5
28-40 weeks (3rd trimester) 16 25.8
Type of operation performed (N = 50)
Lumpectomy 37 74.0
Mastectomy 25 50.0
Immediate reconstruction after mastectomy (N = 25)
Yes 8 32.0
No 17 68.0
Sentinel node biopsy performed (N = 50)
Yes 20 40.0
Methylene Blue tracer 7 35.0
Radiolabeled tracer 12 60.0
Unknown 1 5.0Decisions regarding agent selection and schedule were left
to the discretion of the treating physician after consultation
with patients, although opinion from multidisciplinary
tumor board was considered in many cases as well. All 36
patients received doxorubicin and cyclophosphamide (AC)
and 26 (72.2%) completed 4 cycles during pregnancy;
of those receiving AC, 29 (80.6%) were treated on an
every-3-week basis, and 7 (19.4%) received “dose-dense”
AC every two weeks. Of these 7 patients, 4 received
pegfilgrastim and 2 received filgrastim during preg-
nancy. Three patients (8.3%) received 12 cycles of weekly
paclitaxel during pregnancy following AC. No patients re-
ceived trastuzumab or endocrine therapy during pregnancy.
Maternal outcomes
Of the 68 term pregnancies, 1 was complicated by intrauter-
ine growth restriction (< 10th percentile), 1 by gestational
hypertension, 3 by gestational diabetes, and 3 by cervical
shortening (defined as cervix < 3 cm at 22 weeks gestation).
Other complications of pregnancy, such as preeclampsia
and placental abruption, were not seen. Complications of
chemotherapy, including anemia, neutropenia, and febrile
neutropenia, were rare, and not more common with dose-
dense therapy. One patient required a blood transfusion for
anemia. A total of 13 patients (36.1%) treated with chemo-
therapy developed treatment-related neutropenia; but
most cases were mild, with absolute neutrophil counts
(ANC) >1000. One patient developed febrile neutropenia
and mycoplasma pneumonia requiring hospitalization.
There were very few additional treatment-related com-
plications; specifically, no pulmonary emboli or prolonged
wound infections were seen. One patient with Factor V
Leiden had a superficial blood clot. One patient experi-
enced intraoperative preterm contractions at 30 weeks’
gestation; she underwent successful tocolysis and was in-
duced closer to term.
Fetal outcomes
A total of 68 of 74 patients delivered liveborn infants
(Table 4). Over half of deliveries (37, 54.4%) were at <
37 weeks and thus were considered preterm. However, the
majority of preterm deliveries (26, 70.2%) were planned in
order to facilitate maternal therapy, e.g. continuation of
chemotherapy. The remaining preterm deliveries (11,
29.7% of all preterm, 16.2% of all deliveries) were due to
complications including spontaneous preterm labor or pre-
term premature rupture of membranes. Detailed birth in-
formation was available for 50 infants; missing information
was from patients who delivered at outside hospitals. The
rate of birth weight <10th percentile was 8.0%. All infants
had Apgar scores ≥ 7 at five minutes.
Three patients gave birth to infants born with congeni-
tal anomalies. One infant was found to have a cleft pal-
ate; the mother had other risk factors including tobacco
Table 3 Systemic therapy for pregnancy associated breast
cancer
Systemic therapy (N = 68 patients delivered live
born infants, 36 received chemotherapy therapy)
Number Percent
Chemotherapy during pregnancy (N = 68)
Yes 36 52.9
No 32 47.1
Gestational age at initiation of treatment (N = 36)
0-12 weeks (1st trimester) 0 0.0
13-27 weeks (2nd trimester) 29 80.6
28-40 weeks (3rd trimester) 7 19.4
Chemotherapy regimen (N = 36)
Every-3-week AC 29 80.6
4 cycles 21 72.4
3 cycles 2 6.9
2 cycles 5 17.2
1 cycle 1 3.4
Dose-dense AC 7 19.4
4 cycles 5 71.4
2 cycles 2 28.6
AC × 4 + weekly paclitaxel (12 weeks) 3 8.3
Dose-dense AC 2 66.6
Every-3-week AC 1 33.4
Neoadjuvant chemotherapy (N = 36)
Yes 8 22.2




Abbreviations: AC doxorubicin, cyclophosphamide.
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during pregnancy (Shaw et al. 1996). One infant had an
atrial septal defect noted prior to initiation of chemother-
apy at 31 weeks, after completion of fetal cardiac develop-
ment. One infant was born with multiple abnormalities
(ventricular septal defect, club foot, and hypospadias); the
VSD and club foot were noted prior to initiating breast
cancer therapy at 20 weeks, and hypospadias was addition-
ally seen at delivery.
Discussion
In this cohort of patients with PABC, contemporary ther-
apies for breast cancer including “dose-dense” scheduling,
taxane chemotherapy, growth factor support, immediate
breast reconstruction, and sentinel lymph node biopsy,
were utilized without significant rates of adverse maternal
or fetal events. There was a low rate of maternal complica-
tions, and the overall rate of fetal abnormalities, 4.4%, was
consistent with expected population rates (Parker et al.2010). This series is one of the most modern cohorts of
PABC patients in the current literature, with the major-
ity of patients receiving their diagnosis during or after
the year 2005.
Consistent with prior reports, and likely due to the young
age of the patients, this PABC cohort was enriched for ER-
negative tumors as well as BRCA mutations (Middleton
et al. 2003; Elledge et al. 1993). However, patients’ clinico-
pathologic details did not differ greatly from those noted in
other studies of non-pregnant young women diagnosed
with breast cancer (Collins et al. 2012).
Almost all patients in the cohort underwent imaging to
stage their disease while pregnant. Notably, nearly half of
patients underwent mammography and over 10% under-
went MRI scanning, with no apparent adverse effect on the
fetus. The safety and feasibility of mammography during
pregnancy have been reported (Kopans 1998; Yang et al.
2006), and it is unclear why rates of mammography were
not higher in this population. The findings from this study
support the safety of mammography during pregnancy; and
suggest that MRI may have a role in select cases (Taylor
et al. 2011).
Reports suggest that mastectomy or lumpectomy can be
safely pursued at any point during a pregnancy with min-
imal risk to the fetus (Rosenkranz & Lucci 2005; Amant
et al. 2010). However, first trimester surgery is often de-
ferred, out of concern for higher risks of fetal complica-
tions (Moran et al. 2007). In this cohort, nearly one in five
patients underwent surgery in the first trimester without
apparent complications, suggesting the safety of surgical
intervention during this time. Additionally, both sentinel
lymph node biopsy and immediate reconstruction were
utilized without apparent complication. Overall, very few
surgical complications were observed, consistent with
previous observations (Dominici et al. 2010). These data
support the safety of contemporary surgical treatment
paradigms in PABC, as long as practitioners are aware of
the unique physiologic changes associated with preg-
nancy (Hill & Pickinpaugh 2008).
Although chemotherapy administration during the first
trimester has been associated with risk of fetal defects, the
use of certain chemotherapeutics in the second and third
trimesters is generally considered safe without increase in
the rates of fetal abnormalities (Loibl et al. 2012; Amant
et al. 2010; Cardonick & Iacobucci 2004; Ring et al. 2005).
The chemotherapy data presented in this study support
the safety of administering traditional as well as more
contemporary treatment regimens in this population.
Dose-dense scheduling has an important role in modern
adjuvant breast cancer treatment, however is not typically
offered to women during pregnancy due to concerns re-
garding potential harm to the fetal bone marrow. A prior
study of 10 pregnant patients treated with dose-dense AC
found no difference in maternal or neonatal outcomes
Table 4 Fetal outcomes after treatment for pregnancy
associated breast cancer
Fetal Outcomes
(N = 68 patients delivered live born infants)
Frequency Percent
Method of delivery (N = 68)
Method of delivery known 62 91.2
Spontaneous onset of labor 8 12.9
Induction of labor 38 61.3
Caesarian section 21 33.9
Method of delivery unknown 6 8.8
Gestational age at delivery (N = 68)
Gestational age at delivery known 66 97.1
<34 weeks 4 6.7
34-36.9 weeks 33 50.0
>37 weeks 29 43.9
Gestational age at delivery unknown 2 2.9
Weight for gestational age (N = 68)
Weight for gestational age known 50 73.5
SGA (<10th percentile) 4 8.0
AGA 45 90.0
LGA (>10th percentile) 1 2.0
Weight for gestational age unknown 18 26.5
Apgar scores (N = 68)
Apgar scores known 50 73.5
≤7 at 5 minutes 0 0.0
≥7 at 5 minutes 50 100.0
Unknown 18 26.5
Complications of delivery (N = 68)
Spontaneous preterm delivery 5 7.3
Arrested preterm labor 2 2.9
PPROM 5 7.4
Chorioamnionitis 1 1.5
Cord prolapse 1 1.5
Uterine atony 1 1.5
Fetal Abnormalities (N = 68)
Cleft palate 1 1.5
VSD, club foot, hypospadias 1 1.5
ASD 1 1.5
Abbreviations: SGA small for gestational age, AGA average/appropriate for
gestational age, LGA large for gestational age, PPROM preterm premature
rupture of membranes, VSD ventricular septal defect, ASD atrial septal defect.
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et al. 2012b). In this study, in the patients who received AC,
including the significant minority who received a “dose-
dense” schedule, there were no apparent short-term adverse
effects on offspring.
Most prior studies evaluating chemotherapy in PABC
have examined AC or FAC, but few studies have examinedthe safety of taxanes, which play an integral role in adjuvant
chemotherapy regimens. In this cohort, 8.3% of patients
who received AC also received 12 cycles of weekly paclitaxel
during pregnancy without evident undesirable effects. To
date, the use of taxanes in PABC has been reported primar-
ily as case reports (Potluri et al. 2006; Nieto et al. 2006). In a
recent review of this literature, it was noted that of 42 in-
fants born to 40 patients exposed to taxanes during preg-
nancy, only one had a malformation possibly related to
taxane use (Mir et al. 2010). Further expansion of this data
is desired to confirm the safety of taxane-containing chemo-
therapy regimens after the first trimester.
In non-pregnant women, growth factors may be required
during adjuvant chemotherapy, particularly with “dose-
dense” schedules. There are few reports in the literature of
patients receiving growth factors during pregnancy (Dale
et al. 2003). Consistent with the prior publications, 6 pa-
tients in this study received growth factor support without
apparent adverse effect on the fetus.
Although neither tamoxifen nor trastuzumab has been
rigorously studied in pregnant patients, these important sys-
temic agents are traditionally avoided in pregnancy out of
concern for teratogenic effects. Case reports have described
multiple fetal complications after prenatal exposures to
these agents (Gottschalk et al. 2011; Braems et al. 2011;
Witzel et al. 2008). Trastuzumab has been associated with
oligohydramnios, and a boxed warning for teratogenicity
has been issued, contraindicating the use of trastuzumab in
pregnancy. As a short-term delay in the initiation of endo-
crine therapy likely does not adversely affect survival out-
comes, particularly in early stage breast cancer, it is feasible
to consider delayed initiation of tamoxifen until completion
of pregnancy. However, given the growth kinetics of HER2
positive breast cancer, a delay in HER2-directed therapy
may be more clinically significant and introduce potential
risk of compromise in the care of these patients. Fortu-
nately, current adjuvant regimens for HER2 positive breast
cancer can begin with anthracycline-based chemotherapy,
facilitating postponement of trastuzumab therapy until after
delivery. Analysis of unintentional pregnancies during adju-
vant trastuzumab clinical trials is in process (Azim et al.
2012), and an ongoing prospective study (MotHER preg-
nancy registry) is collecting data on pregnancies compli-
cated by trastuzumab exposure.
In general, increased rates of maternal complications of
pregnancy were not observed in this cohort, possibly
reflecting early inclusion of a maternal-fetal medicine spe-
cialist in the multidisciplinary team. A notable finding
was the observation that over half of deliveries occurred
at < 37 weeks, and were considered preterm. In contrast,
the current expected rate of preterm delivery in the United
States is 12.2% (Martin et al. 2011). With the exception of
one series suggesting rates of preterm delivery comparable
to general population norms (Cardonick et al. 2010), most
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risk of preterm delivery in patients treated with chemo-
therapy for PABC (Smith et al. 2001; Loibl et al. 2012; Van
Calsteren et al. 2010). In this series, the majority of preterm
deliveries were planned to facilitate maternal therapy, e.g.
to allow continuation of chemotherapy. Only 16.2% experi-
enced unplanned preterm delivery, a figure more consist-
ent with national averages for non-PABC patients.
The question of planned premature delivery deserves
examination. Although preterm delivery in this cohort did
not appear to result in increased harm to the fetus, recent
obstetrical data has suggested even late preterm delivery
(34–37 weeks) or near term delivery (37–39 weeks) can be
associated with adverse outcomes in the fetus (Hibbard
et al. 2010; Shapiro-Mendoza et al. 2008). In addition, a re-
cent evaluation of children exposed to chemotherapy in
utero has noted lower cognitive development for those
born preterm than for those born full term (Amant et al.
2012). Given the apparent safety of chemotherapy during
pregnancy, especially in the third trimester, the risks of late
preterm delivery must be carefully considered when plan-
ning the timing of delivery. In these situations, a careful
discussion is encouraged between the patient, the
maternal-fetal medicine specialist, and the medical oncolo-
gist so that delivery timing minimizes risks to both mother
and fetus.
Strengths of this study include utilization of a large aca-
demic comprehensive cancer center, and evaluation of a
sizeable number of pregnant breast cancer patients treated
with more contemporary treatment regimens than have
been previously published. In addition, a systematic ap-
proach was used to assemble the cohort rather than solely
relying on physician recall or patient self-enrollment, elim-
inating a source of bias. Finally, the majority of patients
were treated for their breast cancer and delivered their in-
fants at the same institution, allowing for data capture for
peripartum as well as maternal outcomes.
A limitation of this study is the lack of follow-up data in
exposed infants; data is limited to in utero and perinatal
outcomes. Obtaining retrospective follow-up data is com-
plicated by loss to follow-up and limitations of self-
reported data. However, prospective long-term follow-up
studies have generally demonstrated favorable outcomes in
exposed offspring (Aviles & Neri 2001; Hahn et al. 2006).
Another limitation of this study is sample size; while this
cohort is large compared to other published cohorts of
PABC, the sample size is small in absolute terms, making it
difficult to generate definitive conclusions. In addition, the
study was limited to women treated in a large academic
tertiary care center, which introduces the possibility of se-
lection bias. Data on socioeconomic status was not avail-
able, but it is possible that a higher degree of social and
financial support may have impacted not only treatment
choices but also patient outcomes.This retrospective study of PABC demonstrates the feasi-
bility of optimal treatment through multidisciplinary care
team management. Continued prospective data collection
and case series publication may improve comfort with using
contemporary treatment paradigms to care for women in
the difficult situation of having been diagnosed with breast
cancer while pregnant. When making treatment decisions
for these patients, attention to multidisciplinary team man-
agement is necessary to appropriately balance perinatal care
of mother and infant. Further data collection and investiga-
tion will improve understanding of and treatment para-
digms for breast cancer diagnosed during pregnancy.
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